Thomas E. Ichim, Ph.D. – Chief Executive Officer and Director

Dr. Ichim is a seasoned biotechnology entrepreneur with a track record of scientific excellence. He has founded/co-founded several companies including Batu Biologics, Inc., Medvax Pharma Corp, ToleroTech Inc, bioRASI, and OncoMune LLC. To date, he has published 121 peer-reviewed articles and is co-editor of the textbooks “RNA Interference: From Bench to Clinical Translation” and “Immuno-Oncology Text Book.”

Dr. Ichim is an ad-hoc editor and sits on several editorial boards. Dr. Ichim is an inventor on 135 patents and patent applications. Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. Dr. Ichim spent over 7 years as the President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Dr. Ichim has extensive experience in product development, regulatory filings, and business development.

Dr. Ichim has a BSc in Biology from the University of Waterloo, Waterloo, Ontario, Canada, an MSc in Microbiology and Immunology a University of Western Ontario, London, Ontario, Canada and a Ph.D. in Immunology from the University of Sciences Arts and Technology, Olveston Monserrat.

Ms. Kalina O’Connor – Founder and Chief Visionary Officer

Kalina O’Connor is the daughter of Kathleen Campbell, a victim of suicide who the Division Campbell Neurosciences is named after.  Kalina is a serial entrepreneur having experience in the area of counselling and biotechnology business development.  Kalina worked in various high-end suicide prevention/rehabilitation organizations for a decade, which provided her an intimate understanding of the shortcomings that exist in current approach to brain understanding and reprogramming.  Subsequently, Kalina was engaged with biotechnology organizations such as Therapsol and Bioscientific Holdings, providing introductions to licensing opportunities from academia.  

James Veltmeyer, MD – Chief Medical Officer

Dr. Veltmeyer is a board-certified family physician in La Mesa, California. A graduate of UC San Diego and the Ross University School of Medicine, he completed his residency through the UC San Francisco system where he became Chief of Family Medicine Residency, overseeing 36 doctors.

Dr. Veltmeyer, a member of the San Diego Critical Care Medical Group, has been elected for four years (2012, 2014, 2016, and 2017) by his colleagues in the San Diego County Medical Society as a “Physician of Exceptional Excellence,” the most prestigious honor awarded to a “Top Doctor” in San Diego County. He is among a select group of San Diego physicians who was chosen four of the last fifteen years and he consistently ranks in the top 1% to 2% for patient satisfaction. He is currently the Chief of the Department of Family Medicine at Sharp Grossmont Hospital where he provides senior leadership to over 200 doctors.

Jona Barnes, Chief Financial Officer

Jona Barnes is an accomplished financial executive with over 33 years of experience in private and public companies with exceptionally strong analytical skills.   She is a result driven business partner able to establish vision and drive strategies to strengthen top and bottom-line performance through “roll up the sleeves” hard work.

Jona holds a bachelor’s degree in Accounting from San Diego State University.  She has worked for several public accounting firms. She is a partner for 25 years at Mallett & Barnes Tax Services representing corporate and individual clients with financial management, tax and complex audit issues.

Timothy G. Dixon – Chairman

Mr. Dixon currently serves as Chief Executive Officer, President, and Chairman of Therapeutic Solutions International, Inc. He also currently serves as Chairman of Campbell Neurosciences, Inc., Allogen Biologics, Inc., Res Nov Bio, Inc., and Breathe Biologics, Inc., all subsidiaries of TSOI. Mr. Dixon previously served as the President of TMD Courses, Inc. from 2006 to 2012 and; as the President of Splint Decisions Inc. from 2010 to 2011. Mr. Dixon has produced many educational DVD’s used by dental professionals worldwide on the subject of parafunctional control, migraine prevention, therapeutic Botox injections, migraine pathophysiology, dental sleep medicine, and other therapeutic protocols. Mr. Dixon also has extensive experience in dealing with corporate compliance matters with the U.S. Food and Drug Administration, (FDA) as well as many international regulatory bodies. Mr. Dixon is inventor and co-inventor of 70+ patents and patents pending.